

HTANGEL

Keeping you up-to-date on
HTA decisions

Issue 38: June 2026

June brings strong oncology and respiratory wins, but several high-profile therapies split across markets.

This newsletter summarises final decisions from NICE, SMC, HAS & IQWiG from published reports in June 2026.

Good news

Atogepant, approved for treatment of migraine in England; **Semaglutide**, approved for cardiovascular risk reduction in overweight/obesity in Scotland; and **Tarlatamab**, approved for advanced small-cell lung cancer in France.

Mixed news

Cemiplimab, approved for advanced NSCLC in England but not approved for cutaneous squamous cell carcinoma in Germany; and **Mepolizumab**, approved for severe eosinophilic COPD in England but not in Germany

Bad news

Imlunestrant, not approved for ER+, HER2- breast cancer in Germany and submission terminated in England; **Inebilizumab**, not approved for Ig4-related disease or generalised myasthenia gravis in Germany; and **Niraparib with abiraterone**, not approved for BRCA1/2+ metastatic prostate cancer in Germany and submission terminated in Scotland.

Approvals

25

Non-approvals

20

HTANGEL

Issue 38: June 2026

Pharmacological Technologies




Germany
IQWiG A25-156,
A26-43

Blood

Paroxysmal nocturnal
haemoglobinuria
IPTACOPAN

Not
approved



Germany
IQWiG A26-20

Cancer

Biliary tract cancer
IVOSIDENIB

Not
approved



Germany
IQWiG A26-19

Cancer

Acute myeloid
leukaemia
IVOSIDENIB

Not
approved



Germany
IQWiG A26-17

Cancer

Breast cancer
ABEMACICLIB

Not
approved



France
HAS AP594

Cancer

B-cell lymphoma
EPCORITAMAB

Not
approved



England
NICE TA1168

Cancer

Breast cancer
IMLUNESTRANT

Terminated



England
NICE TA1159

Cancer

B-cell lymphoma
LISOCABTAGENE
MARALEUCEL

Approved
with special
conditions



Germany
IQWiG A26-30

Cancer

Breast cancer
IMLUNESTRANT

Not
approved

HTANGEL


Issue 38: June 2026

Pharmacological Technologies



England
NICE TA1164

Cancer
Cervical cancer
TISOTUMAB VEDOTIN



England
NICE TA1167

Cancer
Lung cancer
SERPLULIMAB



Scotland
SMC2943

Cancer
Follicular lymphoma
TAFASITAMAB



France
HAS AP579

Cancer
Lung cancer
TARLATAMAB



England
NICE TA1160

Cancer
Gastric cancer,
Gastroesophageal junction
cancer
DURVALUMAB



England
NICE TA1170

Cancer
Multiple myeloma
DARATUMUMAB
WITH BORTEZOMIB



England
NICE TA1165

Cancer
Lung cancer
CEMPIPLIMAB



Scotland
SMC2863

Cancer
Multiple myeloma
TALQUETAMAB



HTANGEL

Issue 38: June 2026

Pharmacological Technologies




England
NICE TA1169

Cancer

Ovarian cancer, Fallopian tube cancer, Peritoneal cancer

**MIRVETUXIMAB
SORAVTANSINE**



Germany
IQWiG A25-154,
A26-45

Cancer

**Urothelial cancer
NIVOLUMAB**



Scotland
SMC2940

Cancer

**Prostate cancer
DAROLUTAMIDE**



Germany
IQWiG A26-16

Cardiovascular

**Myocardial infarction
COLCHICINE**



Scotland
SMC2942

Cancer

**Prostate cancer
NIRAPARIB WITH
ABIRATERONE**



Scotland
SMC2872

Cardiovascular

**Myocardial
infarction, Stroke
SEMAGLUTIDE**



Germany
IQWiG A25-155,
A26-44

Cancer


**Skin cancer
CEMPILMAB**



England
NICE TA1161

Cardiovascular

**Pulmonary arterial
hypertension
SOTATERCEPT**



HTANGEL

Issue 38: June 2026

Pharmacological Technologies



Germany
IQWiG A26-18

Endocrine
Endocrine
orbitopathy
TEPROTUMUMAB



Scotland
SMC2827

Genetic & Metabolic
Duchenne muscular
dystrophy
ATALUREN



Germany
IQWiG A26-14

Endocrine
Type 2 diabetes
mellitus
TIRZEPATIDE



England
NICE TA694

Genetic & Metabolic
Familial
hypercholesterolaemia
BEMPEDOIC ACID WITH
EZETIMIBE



Scotland
SMC2843

Gastrointestinal
Cholestasis familial
progressive
ODEVIXIBAT



Germany
IQWiG A26-15

Genetic & Metabolic
Hereditary
angioedema
DONIDALORSEN



England
NICE TA1171

Gastrointestinal
Primary biliary
cholangitis
SELADELPAR



England
NICE TA1172

Neurology
Migraine
ATOGEPAANT



HTANGEL

Issue 38: June 2026

Pharmacological Technologies



Germany
IQWiG A26-27

Neurology
Myasthenia gravis
INEBILIZUMAB



England
NICE TA1162

Neurology
Spinal muscular
atrophy
NUSINERSEN



Germany
IQWiG A25-160

Neurology
Myasthenia gravis
NIPOCALIMAB



England
NICE TA1162

Neurology
Spinal muscular
atrophy
RISDIPLAM



France
HAS AP580

Neurology
Neurofibromatosis
SELUMETINIB



Scotland
SMC2847

Renal
IgA nephropathy
SPARSENTAN



Scotland
SMC2861

Neurology
Neuropathic pain
CAPSAICIN



England
NICE TA1166

Respiratory
Chronic obstructive
pulmonary disease
MEPOLIZUMAB



HTANGEL

Issue 38: June 2026

Pharmacological Technologies



Germany
IQWiG A26-25

Respiratory
Chronic obstructive
pulmonary disease
MEPOLIZUMAB

 Not
approved



Scotland
SMC2941

Respiratory
Progressive fibrosing
interstitial lung disease
NINTEDANIB

 Terminated



Scotland
SMC2851

Respiratory
Rhinosinusitis, Nasal
polyps
DUPILUMAB

 Approved



Germany
IQWiG A26-26

Other
Immunoglobulin G4-
associated disease
INEBILIZUMAB

 Not
approved



Diagnostic Testing



Germany
IQWiG A26-13

Other
Imaging
GADOPICLENOL




HTANGEL

Issue 38: June 2026

Further Information

HTAngel is designed to help keep you up to date with the latest HTA decisions from NICE, SMC, HAS & IQWiG.

Below is a breakdown of the tiles in the newsletter.



At Crystallise we aim to provide an innovative approach to processing information, using software tools to automate processes that are slower and less accurate when done by humans. Our approach provides clients with greater transparency and scope than they could find for the same budget elsewhere. We work with a network of experts and organisations that help us support clients efficiently and effectively, and are proud of our flexible and ingenious way of solving their problems.

For further information about HTAngel contact
newsletter@crystallise.com

To speak to us about our services contact
contact@crystallise.com

